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Abstract
Transanal endoscopic microsurgery (TEM) allows for the resection of large adenomas and early stage cancers in the rectum. The rate
of complications and recurrence for malignant tumors compared with benign tumors has been questioned.
The objective of our study was to analyze the outcome after TEM procedures for adenomas and cancers with focus on local
recurrence and complications.
All 280 patients who had a TEM procedure between January 2008 and September 2015 were enrolled in a prospective cohort
study. Outcome was described for benign and malignant tumors. Mortality, recurrence, and complications were recorded.
Two hundred eighty tumors were treatedwith TEM, 176 (63%) were benign and 104 (37%) weremalignant. Complication rateswere
signiﬁcantly different in the 2 groups, 10.8% (n=19) in the benign and 24.0% (n=25) in the malignant group (P=0.003). A signiﬁcant
difference in perforation/penetration to the peritoneal cavitywas noted (P=0.034). Therewere no signiﬁcant difference in the recurrence
rate of 8.3% (n=13) in the benign and 9.0% (n=7) in the malignant groups. Thirty days mortality rates were 1.1% in the benign group
versus 1.9% in the malignant. Other complications were noted in 2.8% and 3.8% in the benign and malignant group, respectively.
TEM seems to be a safe and viable procedure for removing both benign and malignant lesions from the rectum. TEM offers low
mortality and complication rates also recurrence after resection of malignant tumors.
Abbreviations: ASA = American Society of Anesthesiologists, CT = computed tomography, EMR = endoscopic mucosa
resection, ERUS = endorectal ultrasound, ESD = endoscopic submucosal dissection, MDT = multidisciplinary team, OPEN =
Odense Patient Explorative Data Network, SD = standard deviation, STROBE = Strengthening the Reporting of Observational
Studies in Epidemiology, TEM = transanal endoscopic microsurgery, TME = total mesorectal excision.
Keywords: complications, endoscopic, local resection, polyps, rectal cancer, rectal neoplasms, recurrence, TEM, TEMS
1. Introduction
International experiences have veriﬁed an increase in the amount
of TNM stage T1+T2 cancers from 17% to 40%[1] after the
introduction of screening.
The indications for endoscopic mucosa resection (EMR),
endoscopic submucosal dissection (ESD), transanal endoscopic
microsurgery (TEM), and total mesorectal excision (TME) in
rectal cancer are still debatable. In our institution EMR and ESD
are used for the tumors which, on preoperative endorectal
ultrasound (ERUS), are staged as T0 and TEM is used when
malignancy cannot be excluded with certainty or a T1 stage is
diagnosed. The adenomas treated with TEM in this series are the
large rectal ones as determined by ERUS and macroscopic
morphology.
TME is the standard procedure for the treatment of rectal
cancers more advanced than T1sm2 due to its good oncological
outcome in respect to recurrence and cure,[2] but the rate of major
complications, and procedure related mortality has motivated a
careful selection of patients to TME.[3,4]
One well-established alternative surgical procedure to remove
adenomas and early stage cancer in the rectum is TEM. The TEM
procedure has existed for more than 30 years.[5] The procedure is
a minimally invasive surgical procedure, performed transanally
with a rigid proctoscope and a stereomicroscope which enables
precise endoluminal resection. One major limitation is the lack of
lymph node harvesting from the mesorectum, although locore-
gional excision including parts of the mesorectum has been
described.[6] For cancers our indications for TEM, with the
intention to cure, are tumors less than 5cm in diameter and not
more advanced than T1sm2.[7,8] Preoperative T- and N-staging
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of early cancers are best assessed by ERUS,[9] but preoperative sm
substaging is not possible, which may result in TEM specimens
with a higher T substage than anticipated. If pathology reports do
not show radical resection, or reveals a more advanced T stage or
substage than anticipated, a completion TME is performed.[10,11]
The correct selection of patients for a TEM procedure, or a
major bowel resection like a TME, relies therefore on a correct
preoperative staging and early completion surgery in case of
preoperative under staging.
The objectives of this study are to ensure the quality of the
TEM procedure, by assessing the surgical outcomes for patients
treated with TEM in terms of radical surgery, local recurrence,
mortality, and complications.
2. Methods
To improve the reporting of our observational research, we
followed a checklist of items that should be addressed: the
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE).
This is a STROBE compliant observational descriptive cohort
study, data are used to assess the quality of TEM.
The local database was hosted by OPEN (Odense Patient
Explorative Data Network)[12] with general approval by the
Danish Data Protection Agency, and approved by the local
ethics committee of Southern Denmark (registration number:
s-20140075/2008-58-0035). Informed consent was given from
the patients before data were entered in the database. Data were
prospectively collected in the period of January 2008 to
September 2015. All the TEM procedures, performed at the
surgical unit of Odense University Hospital and Aarhus
University Hospital were registered. Data were entered into a
dedicated database and, in cases of missing data, they were
crosschecked with the patient’s ﬁle. The data collected during the
in-hospital period were: Demographical data and American
Society of Anesthesiologists (ASA)-score determined by the
anesthesiologist, size, and location of the neoplasm and the
intention of treatment as cure, compromise, or palliation.
Histopathological data on the completeness of the excision
and on T stage were entered into the database at the ﬁrst follow-
up appointment. Data on complications, recurrence, and
mortality were collected at all follow-up appointments. The
follow-up program for benign tumors included a rectoscopy after
3 and 12 months if the tumor was excised by a piecemeal
technique or in cases of borderline complete histological
resection. Otherwise a follow-up endoscopy was made after 1
and 3 years. If they were without recurrence, the patient were
offered a follow-up endoscopy every 5th year. For malignant
tumors, follow-up were every 3rd month during the ﬁrst year and
then every 6th month for 2 years and every 12th month for
2 years. Follow-up included endoscopy, digital rectal examina-
tion, and ERUS. A computed tomography (CT) scan of the
thorax and abdomen was offered after 1 and 3 years to all
patients with a malignant tumor. These follow-up regiments
were organized according to national guidelines for benign and
malignant tumors.[13]
The indication for TEM was the presence of advanced large
tumor where malignancy could not be safely excluded or an
early stage carcinoma in the rectum, not more advanced than
T1 N0M0, was demonstrated by ERUS. TEM was also used as
an alternative to radical surgery in some patients with more
advanced T stage and comorbidity, and/or high age, as a
compromise or for palliation, after being discussed in a
multidisciplinary team (MDT) panel. Some patients refused
further treatment after TEM. All TEM procedures were
performed by 1 of 5 certiﬁed and formally trained consultants.
The inclusion criteria were: All patients who underwent TEM
in the 2 departments of surgery, from January 2008 to September
2015.
Complications during surgery were registered by the TEM
surgeon. Complications were stratiﬁed in peri- and postoperative
complications and are classiﬁed as bleeding, unintentional
perforation to the peritoneal cavity, delayed discharge from
the hospital because of pain, or infections, anal incontinence, or
anal stenosis.
Signiﬁcant bleeding during surgery was deﬁned as >100mL.
Intended penetrations to the peritoneal cavity were registered, but
not regarded as a complication, only unintended perforations
were deﬁned as a complication. Complications after the TEM
procedure were registered if reported within 30 days by any
doctor or nurse attending the patient or if the patient contacted
the surgical department. Patient reported complications at the 3-
month follow-up were also registered.
All complications experienced by the patient within the ﬁrst 30
days were registered without regards to severity or the need for
intervention.
Patients, who did not participate in a follow-up program, were
registered as lost to follow-up. Tumor recurrence and time to
tumor recurrence were registered, and stratiﬁed according to the
intention of the treatment (cure, compromise, palliative). No
patients with lymph node disease at ERUS or MRI were accepted
for TEM with the intention to cure. Tumor recurrence is deﬁned
as a new tumor in the rectum following the TEM procedure.
All statistical analyses were conducted with STATA (version
13.1). Data were analyzed using exact methods for binomial
data. A Fischer exact test was used to assess the hypothesis of no
difference in risk for the outcomes of benign and malignant
tumors, with an assumption of categorical data. P values <0.05
were considered signiﬁcant.
3. Results
3.1. Demographics
A total of 280 patients underwent a TEM procedure. They were
stratiﬁed into benign (n=176) and malignant (n=104) disease
(see Table 1 for further demographics). Mean ASA score for
benign and malignant groups were 1.8 (SD=0.8) and 2.1 (SD=
0.8), respectively (P=0.02).
3.2. Complications
Per-operative complications were observed in 4.5% (n=8) and
5.6% (n=6), respectively (P=0.78) (see Table 2). Unintended
penetration to the peritoneal cavity occurred in 2.4% (n=4) and
1.1% (n=1) (P=0.41) while bleeding was present in 0.6% (n=1)
and 2.9% (n=3) (P=0.11) of the cases.
The total postoperative complication rates were 10.8% (n=
19) versus 24.0% (n=25) (P=0.03) in benign and malignant
cases (see Table 3). These included perforation 2.2% (n=4)
versus 7.7% (n=8) (P=0.03). Bleeding occurring before hospital
discharge was 2.8% (n=5) and 7.7% (n=8) (P=0.08) and
bleeding after discharge as 2.8% (n=5) and 4.8% (n=5) (P=
0.50). One patient with bleeding was treated with blood
transfusion, and 2 patients treated with a reendoscopy and a
hemostatic procedure. Forty-two percent (n=5/12) of the
perforations were treated with open surgery: Hartmann’s
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procedure (n=2), low anterior resection (n=2), or suturing via
laparotomy (n=1). Fifty-eight percent (n=7/12) were sutured
transanally during the TEM procedure. The mean in-hospital
time for the patients treated with an open procedure was 15 days
(5–36), and 2.25 days (1–7) for the patients treated endoscopi-
cally. Other complications were present in 2.8% (n=5) in the
benign group: 3 with anal incontinence and 2 with anal stenosis,
and 3.8% (n=4) in the malignant group: 1 patient with a recto-
gluteal ﬁstula, 1 with anal incontinence, and 1 with anal stenosis
(P=0.91) (see Fig. 1).
3.3. Radical resection
Radical resection was determined by the surgeon, and the
pathologist. A radical resection as assessed by the pathologist was
achieved in 77% (n=136) in benign cases and 55% (n=57) in
malignant cases (P<0.05). According to the surgeon 99% (n=
166) had a macro radical excision in the benign group. There
were missing data in 8 cases in that group. Ninety percent (n=84)
were registered as macroradically excised malignant tumors by
the surgeon. Seven cases had missing data. All the resections
determined not complete resection by the pathologist, were
piecemeal resections. Radical resections were noted in 193 cases
according to the pathologist compared to 250 according to the
surgeons. All cases of pathological nonradical resections were
piecemeal resections.
3.4. Recurrence
Eighty-three percent (n=146) of the benign cases and 85% (n=
88) of the malignant cases (P=0.76) were enrolled in the follow-
up protocol as described above. The mean follow-up was 16.4
months (SD: 15.2) in the benign group and 15.2 months (SD:
12.8) in the malignant group. Recurrence were noted in 8.3%
(n=13) and 13.5% (n=14) (P=0.72) in the benign and
malignant group, respectively (see Table 4). TEM procedures
for cure had a recurrence rate of 9% (n=7/78), TEM for
compromise 20% (n=4/20), and TEM for palliation 50% (n=3/
6). In the benign cases the size of the tumors that recurred was
38.5mm26.3mm in largest diameter (SD: 31.0mm23.0
mm). Four tumors had pathological-free margins, 10 were
excised by a piecemeal technique. In the malignant cases the size
of the tumors that recurred was 26.5mm19.1mm (SD: 21.2
mm12.8mm). Six tumors had pathological-free margins, 7
were excised by a piecemeal technique.
Mean time to recurrence was 14 months (SD: 10.0) and 9.5
months (SD: 8.2, P=0.14), respectively.
Ten patients received preoperative radiation therapy and 3 of
them had a recurrence. Time to recurrence was 5.7 months (SD:
3.5). All of them were treated for compromise, because of
comorbidity making them not eligible for TME and underwent
TEM following radiotherapy instead of standard TME. Four
deaths were reported; 2 in the benign and 2 in the malignant
group (1.1% vs 1.9%).
One of them was related to the surgical procedure, 3 of them
died of an advanced cancer disease. One patient with benign
disease died from an advanced, but unrelated malignancy. All of
them had TEMs for palliation or compromise.
4. Discussion
Postoperative complications were more frequent after cancer
resections than after resection of adenomas. The overall
complication rates were higher in cancer surgery. In particular
the rates of unintended perforations to the peritoneumwere more
frequent during cancer resections. Our data show no signiﬁcant
difference in perioperative bleeding in the benign and malignant
TEM’s. The complication rates were low, and comparable to
existing results from similar studies.[14–16] They show infrequent
occurrence of bleeding during surgery for both benign and
malignant TEM, and a low risk of perforation.
Other complications were described, most notably anal
incontinence and stenosis. However, these were too infrequent
to be of statistical signiﬁcance. It should be noted that
preoperative anal function was not assessed.
Table 1
Basic demographics.
Characteristics Benign Malignant P
Total number, n 176 104 NS
Male, n (%) 96 (54.6) 63 (60.6) NS
Age, mean (SD) 69.7 (11.6) 73.1 (11.6) NS
ASA, mean (SD) 1.8 (0.8) 2.1 (0.8) 0.02
ASA=American Society of Anesthesiologists, NS=not signiﬁcant, SD= standard deviation.
Table 2
Perioperative complications.
Outcome
Benign,
n=176
Malignant,
n=104 P
Total, n (%) 8 (4.5) 6 (5.6) 0.78
Conversion to laparotomy, n (%) 3 (1.2) 2 (3.0) 0.27
Perforation to peritoneal cavity, n (%) 4 (2.4) 1 (1.1) 0.41
Bleeding, n (%) 1 (0.6) 3 (2.9) 0.11
Table 3
Postoperative complications.
Outcome
Benign,
n=176
Malignant,
n=104 P
Days to discharge, with complications, mean (SD) 2.1 (7.6) 1.9 (2.8) 0.79
Days to discharge, without complications, mean (SD) 1.2 (3.3) 1.6 (2.4) 0.88
Complications, n (%) 19 (10.8) 25 (24.0) 0.01
Bleeding before hospital discharge, n (%) 5 (2.8) 8 (7.7) 0.08
Bleeding after discharge within 30 days, n (%) 5 (2.8) 5 (4.8) 0.50
Other complications, n (%) 5 (2.8) 4 (3.8) 0.91
Deaths within 30 days postoperatively, n (%) 2 (1.1) 2 (1.9) 0.63
SD= standard deviation.
0.0%
1.0%
2.0%
3.0%
4.0%
5.0%
6.0%
7.0%
8.0%
Bleeding before
hospital
discharge
Bleeding within
30 daysaer
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Perforaon Other
complicaons
Benign
Malign
Figure 1. Other complications included incontinence, strictures, infections,
and pain.
al-Najami et al. Medicine (2016) 95:36 www.md-journal.com
3
Bleeding was not signiﬁcantly different in the 2 groups,
neither before nor after hospital discharge. However, there is a
nonsigniﬁcant tendency toward more frequent bleeding in the
malignant group. Restivo et al[14] found cancer to be the only risk
factor for bleeding when performing TEM, but in our clinic TEM
is performed only when cancer is expected or likely. Few patients
were treated for a rectal bleeding indicating that bleeding is a
self-limiting minor complication and most often manageable
conservatively.
The higher occurrence of perforation in the malignant group
was expected due to the full thickness approach and intended
wider lateral margins when dealing with a cancer. Intraperitoneal
perforation is often described as a major complication in TEM
surgery and may require rescue surgery. In our data 5 patients
were treated for a perforation with open surgery. The remaining
cases were managed by suturing during the TEM procedure.
Perhaps the latter cases should not be considered as a
complication, but as part of the procedure. Our rate of
complications would then be overestimated.
It is evident that early stage T1 cancers of the rectum are well
suited for excision by TEM.[16–18] More advanced cancers may
show a higher risk of complications during TEM surgery.
Different studies demonstrate different complication rates; our
results are comparable to other studies despite a complication
rate of 10.8% and 24.0% in the benign and the malignant group,
respectively, because most of them are minor. The overall
mortality rate was considered low and there were no signiﬁcant
difference between the 2 groups. Furthermore the mortality rates
were based on mortality to unrelated conditions than the TEM
procedure itself, when correlated to that the mortality rate is 0.
Our data showed low rates of complications during surgery, both
with regards to bleeding and perforation. This supports the
general impression that TEM surgery is safe, also when dealing
with malignant lesions of the rectum. The ASA score was higher
in the malignant group, which may contribute to the higher
frequency of complications.
No signiﬁcant difference in recurrence rates between the 2
groups was found. Our results do show a high overall rate of
tumor recurrence of 13.4% in the malignant group. The
recurrence rate after intention to cure was 9% and comparable
to the results presented by others.[16,19]
The mean time to recurrence from benign tumors was 14 and
from malignant 9.5 months. The mean time to recurrence after
irradiated cancers was 14.7 months. This emphasizes the need for
the close follow-up regime, during the ﬁrst year, but also the
second and third year as seen in the standard deviations (SDs).
The close follow-up should be longer after irradiation.
Forty-six patients either declined further follow-up, or no
further follow-up was indicated, because the intention of their
treatment was either palliative or a compromise. There is
discrepancy between the evaluation of complete resection as
judged by the surgeon and the complete resection assessed by
the pathologist. The histological assessment of the complete
resections remains the gold standard and clinical decisions based
on the surgeon’s judgment of the grade of complete resections
should be questioned. In the cases of piecemeal resections,
however, one could argue that the surgeon’s judgment may be
more informative. A recurrence occurred in 2 of 20 cases judged
to have a nonradical resection by the surgeon, both cases were
piecemeal resections. The length of in-hospital stay after benign
and malignant resections is not different.
5. Conclusion
TEM is a safe and viable treatment for rectal tumors, both for
benign and early malignant tumors. TEM is followed by low
mortality and complications rates, and a short hospital stay.
There is a signiﬁcantly higher risk of unintended perforation
when operating for malignant lesions. It may be questioned if
bleeding and perforations managed transanally is truly a
complication. Further studies are needed to address risk factors
with regards to bleeding and perforation.
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